Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.53 |
| ▸ | DGKA | P23743 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.50 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.50 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7837005 | 1.00 | NAAA (0.53) | NAAADGKAHTR2CPRSS1PRSS2 | |
| SCHEMBL7842772 | 1.00 | NAAA (0.53) | NAAADGKAHTR2CPRSS1PRSS2 | |
| SCHEMBL7839343 | 1.00 | NAAA (0.53) | NAAADGKAHTR2CPRSS1PRSS2 | |
| SCHEMBL127314 | 0.98 | NAAA (0.50) | NAAADGKAHTR2CPRSS1PRSS2 | |
| SCHEMBL125163 | 0.92 | DGKA (0.52) | NAAADGKAHTR2CPRSS1PRSS2 | |
| SCHEMBL7829238 | 0.90 | DGKA (0.62) | NAAADGKAHTR2CPRSS1PRSS2 | |
| SCHEMBL7837625 | 0.90 | DGKA (0.62) | NAAADGKAHTR2CPRSS1PRSS2 | |
| SCHEMBL7838591 | 0.90 | DGKA (0.62) | NAAADGKAHTR2CPRSS1PRSS2 | |
| SCHEMBL7838818 | 0.90 | DGKA (0.62) | NAAADGKAHTR2CPRSS1PRSS2 | |
| SCHEMBL420094 | 0.89 | NAAA (0.64) | NAAADGKAHTR2CPRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450319-B2 | Pyrrolopyridazinone compound | UBE INDUSTRIES, LTD. (JP) | 2013-05-28 | — | — | US | disclosed |
| EP-1982986-B1 | PYRROLOPYRIDAZINONE COMPOUND AS PDE4 INHIBITOR | UBE INDUSTRIES (JP) | 2012-03-07 | — | — | EP | disclosed |
| CN-101374844-A | Pyrrolopyridazinone compound | UBE INDUSTRIES (JP) | 2009-02-25 | — | — | CN | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
| EP-0751133-B1 | Pyrimidine compound, and liquid crystal composition and liquid crystal element using the same | MITSUI CHEMICALS INC (JP) | 2001-09-12 | — | — | EP | disclosed |
| EP-0796248-B1 | CARBOSTYRIL DERIVATIVES AS ANTITHROMBOTIC AGENTS | WESTERN THERAPEUTICS INST D (JP) | 2001-08-16 | — | — | EP | disclosed |
| US-6143763-A | Carbostyril derivatives | D. WESTERN THERAPEUTICS INSTITIUTE (JP) | 2000-11-07 | — | — | US | disclosed |
| US-5770108-A | HIGH SPEED RESPONSE, MOLECULAR ORIENTATION, HIGH CONTRAST, RECEPTIVITY | MITSUI TOATSU CHEMICALS, INC. (JP) | 1998-06-23 | — | — | US | disclosed |
| CN-1172478-A | Quinolone derivative antithrombotic agent | OTSUKA PHARMA CO LTD (JP) | 1998-02-04 | — | — | CN | disclosed |
| EP-0796248-A1 | CARBOSTYRIL DERIVATIVES AS ANTITHROMBOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-09-24 | — | — | EP | disclosed |
| WO-1997012869-A1 | CARBOSTYRIL DERIVATIVES AS ANTITHROMBOTIC AGENTS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1997-04-10 | — | — | WO | disclosed |
| EP-0751133-A1 | Pyrimidine compound, and liquid crystal composition and liquid crystal element using the same | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1997-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | NAAA 2716/4885DGKA 3277/4885HTR2C 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.